Joint Action

Osteoarthritis (OA) is the most common form of arthritis. There are currently no effective disease-modifying treatments available to slow or reverse the progression of OA. Drugs such as metformin, which is commonly used to treat type 2 diabetes are generally safe and low cost. Research has been shown that metformin has anti-inflammatory and pro-weight loss effects, suggesting that the use of metformin may be useful in the treatment or prevention of OA. Dr Matthew Baker joins us on this week's episode of Joint Action to discuss this important topic. Dr. Matthew Baker is the Clinical Chief in the Division of Immunology and Rheumatology at Stanford University. He received his bachelor's degree from Pomona College, his medical degree from Harvard Medical School, and his master's degree in Epidemiology and Clinical Research from Stanford University. He completed his Internal Medicine residency at the Massachusetts General Hospital and his Rheumatology fellowship at Stanford University. Dr. Baker has established a clinical research program that is focused on clinical trials, epidemiological studies, and bench-to-bedside translational research. He has designed and led investigator-initiated and industry sponsored clinical trials with a focus on sarcoidosis, IgG4-related disease, and rheumatoid arthritis. In addition, he is the Co-Director of the Stanford Multidisciplinary Sarcoidosis Program and collaborates with other team members to advance sarcoidosis clinical care and research.RESOURCESDevelopment of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a SulfonylureaIncreased risk of osteoarthritis in patients with atopic diseaseCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

Viscosupplementation is a procedure that involves injections of hyaluronic acid, most commonly into the knee joint. In the United States, one in every seven people receive a hyaluronic acid injection as first line treatment for their knee osteoarthritis. However, the effectiveness and safety of viscosupplementation has remained controversial. On this week’s episode of Joint Action, we are joined by Bruno da Costa to discuss viscosupplementation, their effectiveness and safety.Dr. Bruno R. da Costa is Deputy Director of Trial Methodology Program at Nuffield Department of Population Health, University of Oxford, and Associate Professor of Clinical Epidemiology at the Institute of Health Policy, Management and Evaluation, University of Toronto. He has a Ph.D. in Clinical Epidemiology and Biostatistics from the University of Bern in Switzerland, a M.Sc. in Medical Statistics from the University of Leicester in the UK, and a M.Sc. in Physical Therapy from the University of Alberta in Canada. Dr. da Costa is considered to be an influential scientist in the field of musculoskeletal and cardiovascular disease and methodological research on comparative effectiveness. He has co-authored over 100 scholarly peer-reviewed publications, which have been published in prominent peer-reviewed scientific journals such as The New England Journal of Medicine, The Lancet, Journal of the American Medical Association (JAMA), and The BMJ.RESOURCESViscosupplementation for knee osteoarthritis: systematic review and meta-analysisCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

On this week's special episode, we will hear from experts in pain including content from:Jason McDougall (Season 1, Episode 1)Anne-Marie Malfait (Season 2, Episode 14)Lisa Carlesso (Season 3, Episode 7)Tasha Stanton (Season 3, Episode 19)CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

We have spoken about occupational risk factors for osteoarthritis on previous episodes, but one occupation we have not covered is elite level athletes or Olympians. The intense training schedules sometimes lasting up to 6 hours a day make Olympians more susceptible to joint injury. On this week’s episode of Joint Action, we are joined by Dr Debbie Palmer to discuss the prevalence of osteoarthritis in Olympians. Dr Debbie Palmer OLY is a lecturer in research methods and epidemiology. She is a three-time Winter Olympian, and competed in short track speed skating between 1990-2002. Debbie subsequently worked as an exercise physiologist at the University of Bath before completing her PhD in injury epidemiology 2009, and she has worked in sport injury and illness prevention for over 14 years. Debbie’s research focuses on epidemiology, risk and prevention of injury and illness in elite, youth and recreational cohorts, longer-term consequences of sport-related injury, and current and retired athlete health.RESOURCESPrevalence of and factors associated with osteoarthritis and pain in retired Olympians compared with the general population: part 1 – the lower limbPrevalence of and factors associated with osteoarthritis and pain in retired Olympians compared with the general population: part 2 – the spine and upper limbConsequences of injury are greater for Olympians than the general populationCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast

Exercise is a commonly recommended treatment for osteoarthritis. There have been many studies which have shown the benefits of exercise which include improved pain, function, and quality of life. However, more often times than not, exercise is delivered sub-optimally with health care professionals unclear about how to deliver exercise effectively to people with hip or knee OA. On this week’s episode of Joint Action, we are joined by Melanie Holden to discuss. Melanie Holden is a Chartered Physiotherapist with 17 years of experience of applied health research based within the School of Medicine at Keele University in the UK.  She leads the Osteoarthritis Research Group within the Centre for Musculoskeletal Health Research at Keele. Her research focus is optimising the management of musculoskeletal conditions, including osteoarthritis, through rehabilitation (non-drug, non-surgical treatments). RESOURCESVersus Arthritis: Exercising with ArthritisJournal articlesRecommendations for the delivery of therapeutic exercise for people with knee and/or hip osteoarthritis. An international consensus study from the OARSI Rehabilitation Discussion GroupCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast

About 50% of people who have an anterior cruciate ligament (ACL) injury will go on to develop osteoarthritis later down the track. What determines who will go on to develop OA? And is it possible to reduce your risk of developing OA? On this week’s episode, Dr Adam Culvenor joins us to discuss.Dr Adam Culvenor is a Senior Research Fellow and Head of the Anterior Cruciate Ligament (ACL) Knee Injury Group within the La Trobe Sport and Exercise Medicine Research Centre. His research focuses on the outcomes of ACL injuries, in particular the prevention and management of early knee osteoarthritis in young adults following ACL injury and reconstruction.RESOURCESWebsitesLaTrobe University Sport and Exercise Medicine Research Centre BlogThe OPTIKNEE group is working to prevent osteoarthritis after knee injuryJournal articlesOPTIKNEE 2022: consensus recommendations to optimise knee health after traumatic knee injury to prevent osteoarthritisKnee Extensor Strength and Risk of Structural, Symptomatic, and Functional Decline in Knee Osteoarthritis: A Systematic Review and Meta-AnalysisEarly Knee Osteoarthritis Is Evident One Year Following Anterior Cruciate Ligament Reconstruction: A Magnetic Resonance Imaging EvaluationCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast

Over the years, there has been good evidence that certain treatments are of little or no value, provide harm and have substantial costs associated with them. Arthroscopic partial meniscectomy (APM) is not a recommended treatment for osteoarthritis. Despite this, millions of these procedures are still being performed each year. On this week's episode of Joint Action we are joined by Professor Teppo Järvinen to discuss the evidence behind APM and evidence-based medicine.Professor Teppo Järvinen, an orthopaedic surgeon at the department of orthopaedics and trauma at Helsinki University and Helsinki University Central Hospital. Teppo led the Fidelity trial and has a strong interest in the “too much medicine” movement.CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast

Osteoarthritis is a highly prevalent disease affecting many developing and developed countries worldwide. The prevalence of OA depends on which joint is involved – whether it is the knee, hip or hand. Depending on what type of OA you have, it may also play a role in your overall health. On this week’s episode of Joint Action, we are joined by Qiang Liu to discuss the different sites of OA, their prevalence and risk factors.  Dr Qiang Liu is an orthopedic surgeon and associate professor who sees patients with joint diseases and does research on osteoarthritis in Peking University People’s Hospital. Qiang has published studies on the burden of osteoarthritis and exercise therapy for knee/hip osteoarthritis in prestige journals such as the Lancet Rheumatology and Osteoarthritis and Cartilage. Qiang has devoted himself to helping patients with osteoarthritis by applying and promoting strategies overlooked by the healthcare system in China. Together with Prof. Jianhao Lin, Qiang introduced the Good Life with Osteoarthritis from Denmark (GLA:DTM) to China together and has served as the program manager since 2017. They also opened the first private special clinic which focuses on delivering evidence-based non-surgical treatment for osteoarthritis in China. RESOURCESJournal articlesPrevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast